A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE)

Category Primary study
JournalJournal of Clinical Oncology
Year 2024
This article has no abstract
Epistemonikos ID: 906335fcd8e7a359b4ff354e0642287e31d810f7
First added on: Feb 18, 2025